Syneos Health, Inc. (NASDAQ:SYNH) Director Thomas H. Lee Advisors, Llc sold 1,179 shares of the stock in a transaction dated Monday, June 7th. The stock was sold at an average price of $81.20, for a total transaction of $95,734.80. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.
Thomas H. Lee Advisors, Llc also recently made the following trade(s):
- On Wednesday, May 12th, Thomas H. Lee Advisors, Llc sold 89 shares of Syneos Health stock. The stock was sold at an average price of $81.04, for a total transaction of $7,212.56.
Shares of SYNH opened at $84.10 on Friday. The stock has a fifty day simple moving average of $84.09. Syneos Health, Inc. has a fifty-two week low of $50.26 and a fifty-two week high of $90.10. The company has a market capitalization of $8.77 billion, a PE ratio of 44.73 and a beta of 1.84. The company has a debt-to-equity ratio of 0.89, a current ratio of 1.09 and a quick ratio of 1.09.
Institutional investors and hedge funds have recently made changes to their positions in the stock. Harvest Fund Management Co. Ltd bought a new stake in Syneos Health in the first quarter worth $45,000. Allred Capital Management LLC bought a new position in Syneos Health during the first quarter valued at $56,000. AJO LP bought a new position in Syneos Health during the fourth quarter valued at $72,000. Healthcare of Ontario Pension Plan Trust Fund increased its position in Syneos Health by 50.6% during the fourth quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 1,286 shares of the company’s stock valued at $88,000 after acquiring an additional 432 shares during the last quarter. Finally, FORA Capital LLC bought a new position in Syneos Health during the first quarter valued at $106,000. Institutional investors own 90.68% of the company’s stock.
Several equities analysts have weighed in on SYNH shares. KeyCorp lifted their price target on shares of Syneos Health from $76.00 to $90.00 and gave the company an “overweight” rating in a report on Monday, March 8th. Citigroup lifted their price target on shares of Syneos Health from $80.00 to $85.00 in a report on Friday, February 19th. Mizuho lifted their price target on shares of Syneos Health from $82.00 to $90.00 and gave the company a “buy” rating in a report on Friday, April 30th. Truist Securities lifted their price target on shares of Syneos Health from $88.00 to $104.00 and gave the company a “buy” rating in a report on Wednesday, June 2nd. Finally, Barclays started coverage on shares of Syneos Health in a report on Monday, March 8th. They set an “equal weight” rating and a $84.00 price target on the stock. One research analyst has rated the stock with a hold rating and nine have assigned a buy rating to the company. The stock currently has an average rating of “Buy” and a consensus price target of $83.50.
Syneos Health Company Profile
Syneos Health, Inc provides biopharmaceutical outsourcing solutions company in North America, Europe, the Middle East, Africa, the Asia-Pacific, and Latin America. It operates through two segments, Clinical Solutions and Commercial Solutions. The Clinical Solutions segment offers various services spanning Phases I to IV of clinical development, including full service global studies, as well as individual service offerings, such as clinical monitoring, investigator recruitment, patient recruitment, data management, and study startup to assist customers with their drug development process.
Recommended Story: volatile stocks
Receive News & Ratings for Syneos Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syneos Health and related companies with MarketBeat.com's FREE daily email newsletter.